The year in cardiology 2018: prevention
█ Current opinion
Željko Reiner1, Ulrich Laufs2, Francesco Cosentino3, Ulf Landmesser4
1Department of Internal Medicine, University Hospital Centre Zagreb, School of Medicine, Zagreb University, Croatia
2Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig; Leipzig, Germany
3Unit of Cardiology, Department of Medicine Solna, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden
4Department of Cardiology, Charite Universitätsmedizin Berlin; Berlin Institute of Health (BIH); German Center for Cardiovascular Research (DZHK), partner site Berlin, Germany
Cardiovascular prevention has been in the focus of important studies in 2018. Several large-scale clinical studies have further supported the strong association of an unhealthy lifestyle with an increased cardiovascular risk.
New data have become available for the novel treatment approaches for dyslipidemia (including large scale clinical outcomes data for PCSK9 inhibition and recommendations for their use in clinical practice) and novel data on the impact of SGLT2 inhibition on the risk of heart- and kidney failure diabetic patients. More-over, new European Guidelines on Arterial Hypertension have been published in 2018 and several moderate-sized randomized trials have investigated the efficacy and safety of advanced renal denervation treatments in hypertension. In the field of antithrombotic therapy it has become clear that the use of aspirin in primary prevention does not have a favorable risk-benefit ratio, whereas in patients with atherosclerotic cardiovascular disease (CVD) at very high risk, the addition of low-dose factor Xa inhibition to aspirin can provide a net clinical benefit. New data on inflammation as a treatment target for CVD prevention have become available.